Ninth Circuit Clears 2,200-Plus Social-Media Cases for Trial
The Ninth Circuit's August 10 decision in California et al. v. Meta Platforms Inc. et al. (MDL 3047, N.D. Cal.) is the most consequential procedural ruling of the week for the plaintiff PI bar. The panel dismissed interlocutory Section 230 immunity appeals filed by Meta and TikTok, holding that CDA Section 230 'provides a defense to civil liability rather than immunity from suit.' The collateral-order doctrine requires finality before appellate review, and neither defendant could demonstrate that standard is met.
The practical effect: Judge Yvonne Gonzalez Rogers retains her trial schedule for the more than 2,200 consolidated federal cases in MDL 3047. Meta and TikTok may renew their Section 230 arguments after final verdicts, but they cannot pause the docket now. For firms carrying youth mental-health plaintiffs in the federal MDL, this ruling removes a ceiling that had loomed over discovery and bellwether selection for months.
The immunity question is unresolved. The Ninth Circuit explicitly preserved it for post-judgment review, creating a strategic calculus for plaintiff leadership: secure verdicts large enough that Section 230 defenses on appeal still produce meaningful recoveries after remittitur risk is priced in.
Takeaway: The Section 230 immunity clock now runs from final verdicts rather than interlocutory rulings, and counsel in MDL 3047 should treat the trial docket as the only battlefield that matters before 2027.
Supreme Court FIFRA Ruling Forces a Roundup Strategy Pivot
The 7-2 decision in Monsanto Co. v. Durnell, No. 24-1068 (U.S. Supreme Court, June 25, 2026), reversed a $1.25 million Missouri verdict for plaintiff John Durnell, who alleged non-Hodgkin lymphoma from Roundup exposure. The majority held that FIFRA expressly preempts state-law failure-to-warn claims where the manufacturer followed EPA-approved labeling. That ruling directly affects roughly 3,925 cases remaining in Roundup MDL 2741 in the Northern District of California.
Bayer is moving to wind down MDL 2741 and funnel remaining claimants into the $7.25 billion King v. Monsanto class settlement, a 21-year payout structure that received preliminary approval in Missouri state court in March 2026. For firms holding Roundup cases on a standard failure-to-warn theory, the viable path collapsed on June 25.
The plaintiff bar's pivot is toward negligent design and non-label theories not expressly covered by FIFRA preemption. Whether those theories survive dispositive-motion practice under post-Durnell briefing is the next inflection point. Firms that have not audited their Roundup inventory for preemption exposure by theory should treat that as an immediate priority.
Takeaway: Post-Durnell, failure-to-warn claims against Roundup are federally preempted; plaintiff counsel must audit remaining inventory for viable design-defect and negligence theories before Bayer's MDL wind-down motions foreclose that option.
California First: $6M Jury Verdict in Social-Media Addiction JCCP 5255
On March 25, 2026, a Los Angeles County Superior Court jury in JCCP 5255 (Judge Carolyn B. Kuhl) returned the first jury verdict in California's consolidated social-media addiction docket. In K.G.M. v. Meta Platforms & YouTube, the plaintiff recovered $6 million total: $3 million compensatory, apportioned 70% to Meta and 30% to Google, plus $3 million punitive, split $2.1 million against Meta and $900,000 against Google. Judge Kuhl denied post-trial motions on June 9. Both defendants have noticed appeals.
The verdict is significant beyond its dollar amount. It establishes that a California jury will apportion fault between platform defendants in a youth mental-health case and return punitive damages in the same proceeding. The 70/30 compensatory split and the punitive multiplier will be closely watched by plaintiff leadership in JCCP 5255 and MDL 3047 as bellwether sequencing decisions are made.
Three individual TikTok plaintiffs (S.J., P.M.Y., and K.D.B.) settled confidentially with TikTok in Los Angeles Superior Court on August 3 and 4. YouTube settled its individual bellwether on August 27, hours before the jury phase was set to begin. Los Angeles Superior Court is now the most active social-media trial venue in the country by case volume and by verdict history.
Takeaway: The $6M K.G.M. verdict gives California plaintiff counsel a concrete punitive-damages data point for JCCP 5255 bellwether valuation, and the 70/30 apportionment framework signals how juries may treat multi-platform liability in future proceedings.
Uber Assault MDL: Ninth Circuit Revives 3,000 Cases, Affirms Non-Delegable Duty
The Ninth Circuit reversed summary judgment for Uber in the Uber Assault MDL pending before Judge Breyer in the Northern District of California. The panel cited three factors in finding that Uber's own affirmative conduct created a non-delegable duty: its business model, unreturned driver decals that enabled imposter drivers, and documented prior incidents involving impersonators. The independent-contractor shield did not apply on those facts.
Approximately 3,000 cases remain pending in the MDL. A Phoenix, Arizona federal bellwether trial returned an $8.5 million verdict in February 2026. That verdict, combined with the Ninth Circuit's summary-judgment reversal, gives plaintiff leadership a strong position entering the second half of the bellwether schedule.
For plaintiff firms with Uber assault cases outside the MDL, particularly in California where the common-carrier framework applies to transportation network companies, the Ninth Circuit's reasoning on affirmative conduct and prior notice is directly transferable to state-court summary-judgment briefing.
Takeaway: The Ninth Circuit's affirmative-conduct analysis in the Uber MDL gives plaintiff counsel the authority to defeat independent-contractor defenses in rideshare assault cases throughout the circuit's jurisdiction.
California Lien Law: Jacobs v. Papez Streamlines Competing-Claim Disputes
The California Court of Appeal for the Third District held in Jacobs v. Papez (Cal. 3d Dist. 2026) that a single declaratory-relief action may name both the plaintiff-client and a competing lien-claimant attorney as parties. The ruling eliminates the need for separate actions when two counsel assert competing liens on a PI settlement fund, consolidating what was often a multi-front dispute into one proceeding.
For medical providers, including surgical centers, imaging facilities, and treatment practices operating on letters of protection, this ruling has direct operational impact. Competing attorney liens are among the most common reasons settlement disbursement stalls after a case resolves. A single declaratory-relief proceeding that binds all competing claimants reduces the risk of a provider being drawn into sequential litigation over the same fund.
Firms handling cases with co-counsel transitions, referral-fee splits, or disputed fee divisions should update their lien-enforcement protocols to reflect the Third District's holding. The ruling applies directly in San Diego, Orange, and Riverside county practices, where multi-counsel PI settlements are common in high-volume auto and premises cases.
Takeaway: Under Jacobs v. Papez, California PI counsel and their medical-provider partners can consolidate competing attorney-lien claims into a single declaratory-relief action, a procedural tool that should be incorporated into every firm's settlement-disbursement protocol now.
Boston Scientific SCS MDL 3181 Holds Initial Conference; Abbott and Nevro Split Pending
The Boston Scientific Spinal Cord Stimulator MDL 3181, pending before Judge Josephine L. Staton in the Central District of California, held its initial scheduling conference on August 5, 2026, with plaintiff leadership appointed. The Judicial Panel on Multidistrict Litigation set oral arguments for September 24 on whether to create separate MDLs for Abbott and Nevro spinal cord stimulator devices, a structural decision that will determine how the plaintiff bar allocates resources across three manufacturer dockets.
Spinal cord stimulator litigation centers on device-failure, migration, and infection claims. For medical providers, particularly pain management practices, neurosurgeons, and ambulatory surgery centers treating SCS patients, MDL consolidation is a signal to review documentation practices for device-related complications and confirm that records are preserved against incoming litigation-hold requests.
The September 24 JPML argument will determine whether Abbott and Nevro cases remain consolidated with Boston Scientific or split into standalone MDLs. Either outcome creates distinct plaintiff leadership structures and divergent bellwether timelines. The open question before the bar: whether three separate MDLs or a single consolidated docket produces faster resolution for the thousands of SCS device-failure claims already filed, the September 24 oral argument is the last checkpoint before that structure is set.
Takeaway: Whether JPML creates one SCS MDL or three will shape bellwether timelines for thousands of Boston Scientific, Abbott, and Nevro device cases, and plaintiff counsel holding multi-manufacturer SCS inventories need a position on consolidation before oral argument closes on September 24.